Our Team

The people behind Biognosys



Dr. Oliver Rinner, Founder, CEO, Board Director 
Oliver graduated from the University of Tübingen in biochemistry and psychology and then received his PhD in 2005 for his work in the field of psychophysics and molecular genetics from the University of Zurich. He joined the group of Ruedi Aebersold at the ETH Zurich as a PostDoc, where he published key papers and patents in the field of targeted proteomics and founded Biognosys in 2008.


Dr. Lukas Reiter, Chief Technology Officer 
Lukas graduated from the ETH Zurich in biochemistry/molecular biology. For his PhD, he joined the groups of Michael Hengartner and Ruedi Aebersold and received his degree in 2009 from the University of Zurich. He published key bioinformatic papers in the field of shotgun and targeted proteomics. In his research, he focused on the control of error rates and error propagation. This led to the development of mProphet, the first tool to transfer these concepts to targeted proteomics. After completing his PhD he was a PostDoc for one year and in parallel started at Biognosys, working on professionalizing the software development and applying it to novel acquisition techniques such as SWATH.


Dr. Claudia Escher, Chief Operating Officer 
Claudia graduated from the ETH Zurich in Environmental Sciences with a focus on biology and freshwater ecosystems. She obtained her PhD from the University of Basel, Department of Neurobiology (a group of Markus A. Rüegg) and the University of Applied Sciences Northwestern Switzerland for her work in biomarker discovery with mass spectrometry. Claudia joined Biognosys in 2008 and is responsible for the operations department focusing on contract research projects.


Lidia Novak, Chief Financial Officer 
Lidia holds an MSc. in Finance degree from EDHEC Business School in France and a diploma in Financial Management from Saint-Petersburg State University in Russia. She is also a CFA charter holder. Lidia is in charge of finance functions including assessment of strategic initiatives and relations with existing and potential investors. Lidia joined Biognosys from PMI Strategic planning & Business development team. Before this, she held the position of M&A Vice President at BNP Paribas CIB in France and gained extensive investment banking experience advising PE funds and large-cap companies in their M&A and equity capital market transactions across different sectors and geographies.


Board of Directors

Harry Welten, Chairman

Jan Honoré

Dr. Michael Lee

Dr. Winfried Mayer

Dr. Manuel Peitsch

Dr. Christian Wolfrum

Dr. Oliver Rinner, Secretary of the Board


Scientific Advisory Board

Ruedi, a co-founder of Biognosys, is one of the pioneers in the field of proteomics. He serves on the Scientific Advisory Committees of numerous academic and private-sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics.


Johan, Associate Professor at the University of Lund, Sweden, obtained his PhD in a collaboration between Lund University and AstraZeneca R&D Lund. In 2001 he co-founded Ludesi AB. In 2003, Johan joined the Institute for Systems Biology in Seattle and in 2004, he transferred to the Aebersold lab at the ETH Zurich, where he was involved in the development and application of targeted proteomics technologies and co-founded Biognosys.


Paola obtained her PhD from the University of Padova. In 2006, she joined Prof. Ruedi Aebersold’s group at ETH Zurich, where her research received the ETH Latsis Prize 2011. At the beginning of 2011, she started her own research group and was appointed assistant professor at the Institute of Biochemistry at ETH Zurich.


Let us help you do great proteomics!

Please click here to contact us.